patiromer sorbitex calcium (Veltassa)

following an abbreviated submission:

patiromer sorbitex calcium (Veltassa®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of hyperkalaemia in adults.

SMC restriction: in the emergency care setting for the treatment of acute, life-threatening hyperkalaemia alongside standard care.

Patiromer sorbitex calcium offers an additional treatment choice in the therapeutic class of non-absorbed cation-exchange compounds that act as potassium binders.

SMC has previously issued advice for patiromer sorbitex calcium for the treatment of hyperkalaemia in adults with chronic kidney disease stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor therapy to maintain a clinically acceptable serum potassium level (normokalaemia) (SMC2381). This advice remains valid.